ATHN DATA SUMMIT 2015

A Longitudinal, Observational Study of Previously Treated Hemophilia Patients (PTPs) Switching Factor Preparations

ATHN 2 Breakfast Breakout Session

October 30, 2015

athn™ american thrombosis & hemostasis network

Agenda:

Welcome!

- Introductions
- Study Update
- Recruitment
- Good Documentation Practices in Clinical Research
- Feedback and Questions

Current Timeline



Study Update: Recruitment

Study Population

The study will enroll approximately 600 patients with hemophilia and are receiving care from one of the HTCs into:

- Arm A (Prospective): patients who are switching factor replacement products
  - will be followed prospectively for up to 1 year
- Arm B (Retrospective): patients who have switched factor replacement products previously (within the past 50 weeks at the time of enrollment).
  - will be assessed retrospectively and/or followed prospectively for up to 1 year

Study Update: Recruitment

As of 10/15/15

- Site Participation:
  - 15 Sites have agreed to participate, 3 are open
    - Western Pennsylvania, Pittsburgh, PA, Dr. Ragni
    - St. Josephs, Tampa FL, Dr. Cockrell
    - Boston Children's Hospital, Boston, MA, Dr. Croteau
  - More Sites to be recruited (~10) for up to 30 sites
    - Each site should enroll at least 5 subjects
- Accrual to Date
  - Arm A – 1 Subject!
  - Arm B – first subject pending

Study Update: Version 2.0

- Amendment issued September 4, 2015
  - Adds baseline inhibitor screen (Sample stored, or result)
  - Clarifications regarding Arms
  - Updates to Schedule of Assessments (next slide)
  - Other minor clarifications
- Study Manager
  - Forms reflect Version 2.0
- Manual of Operations available
  - Includes tools and forms

Schedule of Assessments: Version 2.0

	CYCLE 1							SUBSEQUENT CYCLES (2 – 7)			
STUDY PROCEDURES *(CRF)*	**SCREEN**	**BASELINE**	10 ED (+/-2), or after 6 months, whichever is sooner **(ED10)**	Ad hoc/ Unscheduled visit between exposure day 1-48 [2, 10] **(ADHOC)**	Q3 Month Interval [7, 10] **PHONE VISIT (Q3)**	50 ED (+/- 2) or 1 year, whichever is sooner [7] **(ED50)**	**FINAL VISIT** [5]	**BASE LINE 2/ Day 1**	**Cycle 2 ED10**	**Cycle 2 ED50**	Q3 Month Interval [7, 10] **PHONE VISIT (Q3)**
Check eligibility [1] *Eligibility Form Demographics Form Concomitant Medications Form*	X										
Informed consent [1]	X										
Hemophilia History Family History [3,4] *Hemophilia & Inhibitor Hx Form*		X									
Factor Switch Plan [6] *Factor Switch Form*		X						X			
On Study Assessment [8,9] *Medical Hx & Phys.Exam Form Concomitant Medications Form Q3 Follow Form SAE Form if applicable*		X		X	X		X	X			X
Targeted Physical Exam *Medical Hx & Phys.Exam Form*		X [10]		X							
Inhibitor Assay (local) [11] *Inhibitor Titer Report Form* **PK Data** (if available) *PK Form*		X [11]	X	X		X	X	X	X	X	
Termination Assessment *End of Cycle/End of Study Form*				X			X				
Confirmatory Inhibitor Sample (Central) *Inhibitor Titer Report Form*				X [12]		X [12]				X	
Product-specific forms as applicable	X	X	X	X		X	X	X	X	X	

What Study Procedures are not "Standard Care?"

- Stored sample for baseline inhibitor assay, if required
- Inhibitor assay at 10 exposure days
- Q3 monthly phone follow up
- Product Specific Modules / Questionnaires

Screening

- Identify patients planning to switch soon (ideally within 1 month)
- Screening performed prior to seeing patient for Consent to determine Eligibility (because the screening would be necessary to switch factors anyway)
- A Screening 'Visit' may not be needed with subject/family.
  - No tests to determine eligibility are required by protocol, other than Inhibitor test to establish baseline, prior to switch

Study Update: Recruitment

Eligibility Questions

- Timing of Baseline Inhibitor Test in relation to Switch
  - Clarified by Arm in Version 2.0, Section 4.1
- Number of Exposures
  - Must not be treatment naïve/PUP
  - Must be 2 years old
  - Must have had at least 50 Exposure Days with previous Factor

Study Update: Recruitment

All recruitment materials must be approved by your IRB prior to use

- Recruitment brochure
  - Available in English and Spanish
  - Brochures to be sent in bulk to sites
  - Sites may add HTC and Contact Information to back panel
- Recruitment script
  - To contact potential subjects by phone.
  - Modify with local site preferences, as appropriate, or use as is
- Powerpoint slides
  - To present at local and regional meetings

Substudies: Product-Specific Modules

- ATHN working with Industry Partners for selected factor products to collect post-approval data
  - Will be limited to questions about factor use, packaging, patient preferences and similar ‘non-clinical’ data
- Substudies are voluntary for subjects
  - Add-on questionnaires to be administered to subjects receiving specific factor products
- Substudy IRB approval may or may not be required by your institution

Substudies: Product-Specific Modules

- Several sponsors in play
  - Contracts and budgets pending
- Update on current strategy
  - Possible addition of a validated Adherence Tool

Feedback on Study Logistics

Open for Discussion

Administration and Project Plans

- Site Administration at your HTC
- Future Plans

Site Administration: Payments

- Schedule: Annual Payments for 2015-2016
- ATHN will send HTC a Payment Report
  - # Patients Completed
  - # Inhibitor Report Forms Completed
  - # Product Specific Modules Completed
- HTC will review and submit as Invoice
- ATHN will pay HTC based on amounts negotiated
- Contact Cynthia Branch cbranch@athn.org
  - ATHN National Contract Manager

Contract / Budget

Questions and Feedback

Currently in Development

- Manual of Operations Updates as needed
- Requests?

Future Plans

- Factors presently in pipeline
  - Each becomes eligible as a study product as it achieves FDA approval
- Not every manufacturer will opt for a product-specific module
- Ideally we will catch future factors mostly or entirely in Arm A (prospective)

If your HTC wants to participate in ATHN 2

- Contact Dr. Neufeld or any member of the ATHN 2 Steering Committee to express interest
- Submit Current Protocol and Informed Consent Template to your IRB, or to Western/Copernicus (WIRB)
- Work with ATHN on Contract Execution
  - Cynthia Branch, National Contracts Manager, ATHN
- Participate in Site Initiation Webinar
  - Ellen McCarthy, Clinical Research Project Manager, ATHN

Other Questions?

Open for Discussion

athn™ american thrombosis & hemostasis network

ATHN 2 RESEARCH STUDY

Thank You!

Good Documentation Practices for Clinical Research

2

athn™ american thrombosis & hemostasis network

ATHN 2 RESEARCH STUDY

Securing Data.
Advancing Knowledge.
Transforming Care.